Premium
Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin‐converting enzyme inhibitor
Author(s) -
FUSELLIER M.,
DESFONTIS J.C.,
MADEC S.,
GAUTIER F.,
MARESCAUX L.,
DEBAILLEUL M.,
GOGNY M.
Publication year - 2005
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.2005.00685.x
Subject(s) - benazepril , enalapril , renal function , angiotensin converting enzyme , medicine , pharmacology , beagle , urology , endocrinology , chemistry , blood pressure
The objective of this study was to investigate renal function in clinically normal dogs receiving tepoxalin, a nonsteroidal inflammatory drug, either in association with or without an angiotensin‐converting enzyme inhibitor (ACEI). Ten adult female Beagle dogs were used in the three phases of the study. The dogs were administered the drugs once daily for 7 days (experiment 1: placebo/tepoxalin/tepoxalin and benazepril; experiment 2: enalapril/tepoxalin and enalapril) or for 28 days (experiment 3: tepoxalin and benazepril together). Renal function was assessed by measurement of glomerular filtration rate (GFR) by renal scintigraphy [(renal uptake of 99m Tc‐diethylenetriaminepentacetic acid (DTPA)] and plasma clearance of 99m Tc‐DTPA. Compared with the placebo group, renal uptake and plasma clearance of 99m Tc‐DTPA were not significantly modified after a 7‐day period of treatment with tepoxalin or enalapril alone, tepoxalin and benazepril or tepoxalin and enalapril together. No significant change was obtained in GFR after a 28‐day period of dosing with tepoxalin and benazepril together. Therefore, it was concluded that tepoxalin did not alter renal function in healthy Beagle dogs receiving ACEI.